Dr Paul R Kuraguntla, MD | |
1333 Southview Dr, Bluefield, WV 24701-4317 | |
(304) 327-2907 | |
(304) 327-2989 |
Full Name | Dr Paul R Kuraguntla |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Location | 1333 Southview Dr, Bluefield, West Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1134183361 | NPI | - | NPPES |
5701003000 | Medicaid | WV |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | 19940 (West Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Paul R Kuraguntla, MD 1333 Southview Dr, Bluefield, WV 24701-4317 Ph: (304) 327-2907 | Dr Paul R Kuraguntla, MD 1333 Southview Dr, Bluefield, WV 24701-4317 Ph: (304) 327-2907 |
News Archive
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
For the first time a "tipping point" molecular link between the blood sugar glucose and Alzheimer's disease has been established by scientists, who have shown that excess glucose damages a vital enzyme involved with inflammation response to the early stages of Alzheimer's.
Consultant Urological Surgeon Martin Moody FRCS, to present case for safer surgery alongside Henry Schniewind of HAT in Val d'Isère during the medical conference, Doctors Updates.
ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.
› Verified 1 days ago
John Dybunpin Onglatco, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 324 North St, Suite 2, Bluefield, WV 24701 Phone: 304-327-3408 Fax: 304-324-7967 |